Related Experiment Video
Updated: Jan 18, 2026
10:33
Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
Published on: April 29, 2014
11.5K
Integrative Multiscale Analysis Reveals EFNA1-Driven Immune Remodeling Promotes Colorectal Cancer Lymph Node
Wu Ning1, Nan Qiao1, Lei Zhou1
1Department of General Surgery, China-Japan Friendship Hospital, Beijing, China, zryhyy.com.cn.
Human Mutation
|January 16, 2026
Summary
Researchers identified a distinct cancer cell group driving colorectal cancer metastasis, controlled by IRF9 and communicating via EFNA1. Targeting EFNA1 with Linifanib may improve treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Nodal involvement is critical for colorectal carcinoma prognosis.
- Transcriptional control of lymphatic spread and tumor microenvironment interactions is poorly understood.
- Bulk sequencing lacks resolution for metastatic subclones.
Purpose of the Study:
- To identify and characterize metastasis-driving malignant cell populations in colorectal carcinoma.
- To elucidate the molecular mechanisms and intercellular communication networks involved in colorectal cancer metastasis.
- To explore potential therapeutic strategies targeting metastatic colorectal cancer.
Main Methods:
- Integrated analysis of TCGA, GEO, and single-cell transcriptomic data (266,995 cells).
- Phenotype-guided computational algorithm to identify metastasis-associated malignant populations.
- Gene regulatory network inference, transcription factor activity analysis, and ligand-receptor pairing.
- Experimental validation including genetic perturbations and drug sensitivity assays.
Main Results:
- A distinct malignant cell population associated with lymph node metastasis and poor outcomes was identified.
- IRF9 was identified as the master regulator of this metastatic program.
- Metastatic cells exhibit enhanced communication networks, including VEGF-driven angiogenesis and integrin-laminin adhesion.
- EFNA1 is a key mediator in this subset, correlating with disease progression and suggesting immunoevasion.
- Efna1 ablation impaired cancer cell functions and increased sensitivity to Linifanib.
Conclusions:
- A transcriptionally defined malignant population under IRF9 control drives metastatic progression and reprograms the tumor microenvironment via EFNA1.
- The combination of EFNA1 targeting and Linifanib shows potential for treating metastatic colorectal carcinoma by overcoming anti-angiogenic resistance.
